NeuroOne Medical Technologies Corporation

What they do

NeuroOne develops thin-film electrode technology for brain and spinal cord applications, including diagnostic electrodes used in stereo-electroencephalography (sEEG) procedures and the OneRF Brain Ablation System for radiofrequency thermocoagulation. The company also has a drug delivery platform, StereoCED, intended to combine precision intracranial drug delivery with simultaneous neural recording. It sells products through a distribution relationship and is expanding internationally after receiving ISO 13485:2016 certification.

Revenue drivers

• Product revenue (electrode and ablation devices) — The company's principal revenue source; product revenue rose 16% year over year to $2.0 million in the quarter ended June 30, 2026, with product gross margins of 59.9%.
• sEEG diagnostic electrodes — Disposable thin-film electrodes used for surgical diagnosis of epilepsy and other neurological conditions; the base of the commercial business.
• OneRF Brain Ablation System — Radiofrequency thermocoagulation used with sEEG guidance; a Mayo Clinic Jacksonville study published in the Journal of Neurosurgery supports its use in patients with implanted neuromodulation devices.
• StereoCED drug delivery platform — Pre-commercial; expected to be available for animal research and FDA IDE-approved studies by the end of fiscal 2026, and being used in Mayo Clinic and University of Minnesota collaborations, but not yet generating product revenue.

Recent performance

For the quarter ended June 30, 2026, product revenue was $2.0 million, up 16% from $1.7 million a year earlier, and product gross margin expanded to 59.9% from 53.9%. Product orders of $2.7 million in the quarter exceeded recognized revenue, leaving backlog of $1.7 million as of June 30, 2026. For fiscal year 2026 to date, the company reported receiving $11.2 million in product orders, though recognized revenue is expected to be $9.2 million to $10.5 million because of manufacturing completion and shipment timing. Recent quarterly revenue has been uneven: $2.7 million in the September 2025 quarter, $2.9 million in the December 2025 quarter, $1.9 million in the March 2026 quarter, and $2.0 million in the June 2026 quarter. Cash and equivalents were $2.0 million at June 30, 2026, down from $6.6 million at September 30, 2025.

Strategy

Management is focused on growing product shipments, with fiscal 2026 recognized revenue guided to $9.2 million to $10.5 million while working with manufacturing partners to maximize shipments. The company received ISO 13485:2016 certification and plans international expansion. It is advancing the StereoCED drug delivery platform toward availability for animal research and FDA IDE-approved studies by the end of fiscal 2026, supported by collaborations with Mayo Clinic and the University of Minnesota. A lead investor increased its ownership of outstanding common stock from 7.4% to 12.5% after quarter end. A May 2026 8-K stated that previously issued financials should not be relied upon, and the company filed a 10-K/A on January 23, 2026.

Risks

• Manufacturing and shipment timing — Recognized revenue for fiscal 2026 is guided below product orders received because of manufacturing completion and shipment timing, so orders may not convert to revenue as expected.
• Limited cash and operating losses — Cash and equivalents fell to $2.0 million at June 30, 2026 from $6.6 million at September 30, 2025, while the company continues to report net losses.
• Restatement and disclosure control issues — A May 22, 2026 8-K stated that previously issued financials were not reliable, and a 10-K/A was filed on January 23, 2026 to provide Part III information after the proxy statement was not filed timely.
• Early-stage drug delivery platform — StereoCED is not yet commercially available and is expected only for animal research and FDA IDE-approved studies by the end of fiscal 2026, so its revenue potential is unproven.

Outlook

Management expects fiscal 2026 recognized revenue of $9.2 million to $10.5 million, depending on manufacturing completion and shipment timing, with unshipped orders contributing to backlog. The company says it is working with manufacturing partners to maximize product shipments through the end of the fiscal year. It also expects the StereoCED platform to be available for animal research and FDA IDE-approved studies by the end of fiscal 2026, and it plans international expansion following ISO 13485 certification.